» Articles » PMID: 34145431

Diagnosis and Management of Migraine in Ten Steps

Abstract

Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up.

Citing Articles

Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for Treatment.

Waliszewska-Prosol M, Grandi G, Ornello R, Raffaelli B, Straburzynski M, Tana C Neurol Ther. 2025; .

PMID: 40085393 DOI: 10.1007/s40120-025-00720-2.


Prevalence and Factors with Potentially Inappropriate Prescribing among Older Surgical Outpatients in China: A Nationwide Cross-sectional Study in 100 Hospitals.

Tian F, Chen Z, Zhang J, Zhang Y, Feng Q J Epidemiol Glob Health. 2025; 15(1):39.

PMID: 40072651 PMC: 11903986. DOI: 10.1007/s44197-025-00378-x.


Chronic Stress and Headaches: The Role of the HPA Axis and Autonomic Nervous System.

Sic A, Bogicevic M, Brezic N, Nemr C, Knezevic N Biomedicines. 2025; 13(2).

PMID: 40002876 PMC: 11852498. DOI: 10.3390/biomedicines13020463.


Disproportionality analysis from World Health Organization data on migraine-specific medications and cerebrovascular diseases.

Cho J, Jo H, Park J, Lee K, Lee H, Kim S Eur J Clin Pharmacol. 2025; .

PMID: 39994041 DOI: 10.1007/s00228-025-03812-y.


Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine.

Li M, Huang S, Li J, Hu X, Chen J Drug Des Devel Ther. 2025; 19:1231-1247.

PMID: 39991088 PMC: 11847418. DOI: 10.2147/DDDT.S499848.


References
1.
Goadsby P, Wietecha L, Dennehy E, Kuca B, Case M, Aurora S . Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019; 142(7):1894-1904. PMC: 6620826. DOI: 10.1093/brain/awz134. View

2.
. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

3.
Bigal M, Liberman J, Lipton R . Age-dependent prevalence and clinical features of migraine. Neurology. 2006; 67(2):246-51. DOI: 10.1212/01.wnl.0000225186.76323.69. View

4.
Jackson J, Shimeall W, Sessums L, DeZee K, Becher D, Diemer M . Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010; 341:c5222. PMC: 2958257. DOI: 10.1136/bmj.c5222. View

5.
Lipton R, Dodick D, Ailani J, Lu K, Finnegan M, Szegedi A . Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019; 322(19):1887-1898. PMC: 6865323. DOI: 10.1001/jama.2019.16711. View